These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 10850358)
1. A revolution in the treatment of non-Hodgkin's lymphoma. DeNardo GL; O'Donnell RT; Oldham RK; DeNardo SJ Cancer Biother Radiopharm; 1998 Aug; 13(4):213-23. PubMed ID: 10850358 [TBL] [Abstract][Full Text] [Related]
2. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. Fietz T; Thiel E Recent Results Cancer Res; 2007; 176():153-63. PubMed ID: 17607923 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas. Lim SH; Marcus RE Blood Rev; 1992 Sep; 6(3):157-62. PubMed ID: 1422284 [TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Kaminski MS; Armitage JO J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-54-8. PubMed ID: 23570101 [No Abstract] [Full Text] [Related]
11. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Otte A; Dierckx RA Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349 [No Abstract] [Full Text] [Related]
12. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737 [No Abstract] [Full Text] [Related]
13. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924 [No Abstract] [Full Text] [Related]
14. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: moving targets. van Oers MH Neth J Med; 2009 Sep; 67(8):309-10. PubMed ID: 19767656 [No Abstract] [Full Text] [Related]
15. Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Appelbaum FR Hematol Oncol Clin North Am; 1991 Oct; 5(5):1013-25. PubMed ID: 1938754 [TBL] [Abstract][Full Text] [Related]
16. The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma. Kozuch P; Grossbard ML Clin Lymphoma; 2000 Sep; 1(2):158-9. PubMed ID: 11707826 [No Abstract] [Full Text] [Related]
17. Treatment approaches and nursing considerations for non-Hodgkin's lymphoma. Long J; Versea L Semin Oncol Nurs; 2006 May; 22(2):97-106. PubMed ID: 16720232 [TBL] [Abstract][Full Text] [Related]
18. New therapeutic approaches to non-Hodgkin's lymphomas. Lambert JF; Elfenbein GJ Med Health R I; 2003 Aug; 86(8):236-9. PubMed ID: 14582217 [No Abstract] [Full Text] [Related]
19. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. Kaminski M Cancer Biol Ther; 2007 Jul; 6(7):996-7. PubMed ID: 19358342 [No Abstract] [Full Text] [Related]